News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 690
- Sources here
- 17
- Companies here
- 18
Active search
690 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
COMPASS Pathways (CMPS) Is Up 8.8% After Q2 Net Loss Surges To US$254 Million – Has The Bull Case Changed?
COMPASS Pathways reported a significant net loss of US$253.79 million in Q2 2026, a sharp increase from the previous year, with losses per share at US$1.88. This surge in expenses comes as the company remains pre-revenue, intensifying focus on its ability to fund the …
COMPASS PATHWAYS ($CMPS) Releases Q2 2026 Earnings
This article first appeared on GuruFocus. Cash Position: $433 million in cash on hand as of June 30, 2026, expected to fund operations through launch and into 2028. Regulatory Milestone: Rolling NDA submission for COMP360 in treatment-resistant depression (TRD) underway; completion expected in the …
COMPASS Pathways plc Q2 2026: Revenue $0 Net loss $253.8M, EPS $(1.88) — 10-Q Summary
COMPASS Pathways plc reported a net loss of $253.8M, or diluted loss per share of $(1.88), for Q2 2026, with no product revenue as it remains a clinical-stage company. The company achieved positive primary endpoints in Phase 3 trials for treatment-resistant depression and advanced …
Compass Pathways (Nasdaq: CMPS) posts $253.8M Q2 loss and builds COMP360 launch
Compass Pathways reported a Q2 2026 net loss of $253.8 million, largely due to a non-cash loss from warrant liabilities, compared to $38.4 million in Q2 2025. Despite the widened loss, the company is making significant progress with its COMP360 psilocybin treatment for treatment-resistant …
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360's potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to …
PATTERSON UTI ENERGY INC 2026: Revenue $1.23B, Net income ($19.6M), EPS ($0.05) — 10-Q Summary
Patterson-UTI Energy Inc. reported its 2026 financial results, showing revenue of $1.23 billion, a net loss of ($19.6 million), and diluted EPS of ($0.05). These figures represent an improvement compared to the prior year quarter. The company saw increased revenue momentum, driven by stronger …
Amazon Partner Sets Up After 73% Surge, With Earnings On Watch
Pattern Group is finding support at its 50-day moving average as the stock carves a base that could offer a proper buy point at 29.80. Continue Reading
Compass Pathways Launches Proposed $150.0 Million Public Offering
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced a proposed public offering of $150.0 million in American Depositary Shares (ADSs) and pre-funded warrants. The company may also grant underwriters an option to purchase an additional $22.5 million …
Patrick Industries Reports Mixed Quarter, Diversified Growth Offsets Rv Weakness
Patrick Industries reported essentially flat second-quarter net sales of $1.04 billion, with growth in its marine, powersports, and housing segments offsetting continued weakness in the recreational vehicle (RV) market. Despite a decline in operating income, net income increased significantly due to strategic diversification and …
Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally
Quick Read Palantir's Q2 revenue surged 93% to $1.94 billion, beating consensus, with U.S. commercial total contract value hitting a record $2.1 billion. PLTR rocketed 16% while AI and PATH caught zero sympathy bid, confirming this as a pure single-stock reaction to earnings. Palantir …
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing
Compass Pathways PLC (CMPS) saw muted stock gains despite announcing positive 26-week data from its COMP360 trial for treatment-resistant depression, which confirmed the drug's rapid onset and durability. Analysts maintained "Buy" or "Outperform" ratings, emphasizing the long-term market opportunity and the drug's clean safety …
PTEN Jumps 20% in a Month as Rig Pricing and Demand Strengthen
Patterson-UTI Energy, Inc. (PTEN) shares have increased by 20% over the past month due to improving U.S. drilling activity, equipment utilization, and service pricing. Despite this rally and strengthening operating conditions, the company still faces earnings and commodity risks, with projected net losses and …
Compass Pathways PLC expected to post a loss of 40 cents a share - Earnings Preview
Compass Pathways PLC (CMPS) is projected to report a loss of 40 cents per share in its upcoming earnings announcement. This information is derived from a Refinitiv earnings preview. The full article can be accessed on TradingView, which aggregates news from various sources including …
Patterson-UTI Energy Q2 Earnings & Revenues Beat Estimates
Patterson-UTI Energy (PTEN) reported strong Q2 2026 results, with adjusted earnings breaking even against an expected loss and total revenues exceeding estimates by 7%. This outperformance was driven by robust activity and pricing in its Completion Services segment and improved performance in Drilling Products …